The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia
Status:
Not yet recruiting
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
A randomized controlled pilot study on the safety & efficacy of imatinib for the treatment of
patient with moderate to severe SARS-COV-2 induced pneumonia.